TABLE 3. Characteristics and properties of tick-borne encephalitis vaccine.

Vaccine characteristic	Vaccine property
Trade name	Ticovac
Vaccine type	Inactivated, whole virus
TBE virus strain	Neudoerfl (European TBE virus subtype)
Substrate	Chick embryo fibroblast cells
Adjuvant	Aluminum hydroxide
Stabilizer	Human serum albumin
Preservative	None
Other constituents	Sodium chloride, dibasic sodium phosphate, and monobasic potassium phosphate
Substances used in manufacturing that might be present in final product	Formaldehyde; sucrose; protamine sulfate; trace amounts of neomycin, gentamicin, and chick protein; and DNA from chick embryo fibroblast cells
Final preparation	Suspension for injection
Presentation	Prefilled syringe
Storage	36°F–46°F (2°C–8°C)
Route	Intramuscular
Dose by age group	Aged ≥16 years: 0.5 mL (adult presentation) Aged 1–15 years: 0.25 mL (pediatric presentation)
Primary schedule by age group	Aged ≥16 years: 3 doses administered as follows: Dose 1: On day 0 Dose 2: 14 days–3 months after dose 1 Dose 3: 5–12 months after dose 2 Aged 1–15 years: 3 doses administered as follows: Dose 1: On day 0 Dose 2: 1–3 months after dose 1 Dose 3: 5–12 months after dose 2
Booster dose	All age groups: ≥3 years after completion of the primary series (if ongoing exposure or re-exposure to TBE virus is expected). No Advisory Committee on Immunization Practices recommendations are made on the need for subsequent booster doses.

Abbreviation: TBE = tick-borne encephalitis.